LADENBURG THALM/SH SH lowered shares of Avadel Pharmaceuticals (NASDAQ:AVDL) from a buy rating to a neutral rating in a research note released on Friday morning, Marketbeat reports.
AVDL has been the topic of several other reports. Zacks Investment Research downgraded shares of Avadel Pharmaceuticals from a buy rating to a sell rating in a research note on Thursday, November 8th. ValuEngine raised shares of Avadel Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, January 2nd. Finally, Laidlaw downgraded shares of Avadel Pharmaceuticals from a buy rating to a hold rating and set a $6.00 price target on the stock. in a research note on Tuesday, November 6th. One research analyst has rated the stock with a sell rating and six have given a hold rating to the stock. The company currently has a consensus rating of Hold and an average target price of $6.42.
NASDAQ:AVDL opened at $2.26 on Friday. The company has a current ratio of 3.15, a quick ratio of 3.02 and a debt-to-equity ratio of 1.74. Avadel Pharmaceuticals has a twelve month low of $1.69 and a twelve month high of $9.98.
Avadel Pharmaceuticals Company Profile
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.
Read More: Futures Contract
Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.